ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - pneumococcal polysaccharide serotype 1; pneumococcal polysaccharide serotype 14; pneumococcal polysaccharide serotype 18c; pneumococcal polysaccharide serotype 19 f; pneumococcal polysaccharide serotype 19a; pneumococcal polysaccharide serotype 23f; pneumococcal polysaccharide serotype 3; pneumococcal polysaccharide serotype 4; pneumococcal polysaccharide serotype 5; pneumococcal polysaccharide serotype 6a; pneumococcal polysaccharide serotype 6b; pneumococcal polysaccharide serotype 7f; pneumococcal polysaccharide serotype 9v - תרחיף להזרקה - pneumococcal polysaccharide serotype 23f 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 19 f 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 14 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 9v 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 7f 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 6b 4.4 mcg / 0.5 ml; pneumococcal polysaccharide serotype 5 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 4 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 1 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 3 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 6a 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 18c 2.2 mcg / 0.5 ml; pneumococcal polysaccharide serotype 19a 2.2 mcg / 0.5 ml - pneumococcus, purified polysaccharides antigen conjugated - pneumococcus, purified polysaccharides antigen conjugated - active immunisation for the prevention of disease caused by streptococcus pneumoniae serotypes 1,3,4,5,6a, 6b, 7f, 9v, 14,18c,19a,19f, 23f (including sepsis, meningitis, bacteraemia, pneumonia and acute otitis media) in infants and children from 2 months to 5 years of age.in adults 50 years of age and older, prevnar 13 is indicated for: active immunization for the prevention of pneumonia and invasive disease caused by streptococcus pneumoniae serotypes 1, 3, 4, 5, 6a, 6b, 7f, 9v, 14, 18c, 19a, 19f and 23f. this indication is based on immune responses elicited by prevnar 13. there have been no controlled trials in adults demonstrating a decrease in invasive pneumococcal disease or pneumococcal pneumonia after vaccination with prevnar 13.

ישראל - עברית - Ministry of Health

"טבע מדיקל (שיווק) בע""מ" - אחות - תמיסות סטריליות לשטיפה

ישראל - עברית - Ministry of Health

קיור מדיקל אנד טכניקל סופלאי - רופא - לשטיפה ואיריגציה

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - sirolimus - תמיסה (פומי) - sirolimus 1 mg/ml - sirolimus - sirolimus - rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. it is recommended that rapamune be used initially in combination with cyclosporine microemulsion and corticosteroids for 2 to 3 months. rapamune may be continued as maintenance therapy with corticosteroids only if cyclosporine can be progressively discontinued.

ישראל - עברית - Ministry of Health

abbott medical laboratories ltd, israel - omega-3 acid ethyl esters - קפסולות - omega-3 acid ethyl esters 1000 mg - omega-3-triglycerides - omega-3-triglycerides - post myocardial infarction: adjuvant treatment in secondary prevention after myocardial infarction, in addition to other standard therapy (e.g. statins, antiplatelet drugs, betablockers, ace inhibitors). hypertriglyceridaemia: endogenous hypertriglyceridaemia as a supplement to diet when dietary measures alone are insufficient to produce an adequate response: - type iv hypertriglyceridaemia. - type iib/iii hypertriglyceridaemia in combination with statin, when control of triglycerides by statins is insufficient.

ישראל - עברית - Ministry of Health

lapidot medical import and marketing ltd - soya oil; triglycerides, medium-chain - תחליב לאינפוזיה - triglycerides, medium-chain 50 mg/ml; soya oil 50 mg/ml - combinations - combinations - source of calories and essential fatty oils for patients requiring parenteral nutrition

ישראל - עברית - Ministry of Health

cure medical & technical supply - purified fish oil; refined olive oil; soya oil; triglycerides, medium-chain - תחליב לאינפוזיה - triglycerides, medium-chain 60 g/l; soya oil 60 g/l; refined olive oil 50 g/l; purified fish oil 30 g/l - combinations - combinations - supply of energy and essential fatty acids and omega-3 fatty acids to patients who weight not less than 1 kg, as part of a parenteral nutrition regimen, when oral or enteral nutrition is impossible, insufficient or contra-indicated.

ישראל - עברית - Ministry of Health

cure medical & technical supply - purified fish oil; refined olive oil; soya oil; triglycerides, medium-chain - תחליב לאינפוזיה - triglycerides, medium-chain 60 g/l; soya oil 60 g/l; refined olive oil 50 g/l; purified fish oil 30 g/l - combinations

ישראל - עברית - Ministry of Health

cure medical & technical supply - purified fish oil; refined olive oil; soya oil; triglycerides, medium-chain - תחליב לאינפוזיה - triglycerides, medium-chain 60 g/l; soya oil 60 g/l; refined olive oil 50 g/l; purified fish oil 30 g/l - combinations

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - sirolimus - תמיסה (פומי) - sirolimus 1 mg/ml - sirolimus - sirolimus - rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. it is recommended that rapamune be used initially in combination with cyclosporine microemulsion and corticosteroids for 2 to 3 months. rapamune may be continued as maintenance therapy with corticosteroids only if cyclosporine can be progressively discontinued.